Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Julie Ribot"'
Autor:
Soraia Lobo-Martins, Patrícia Corredeira, Ana Cavaco, Carolina Rodrigues, Paulina Piairo, Cláudia Lopes, Joana Fraga, Madalena Silva, Patrícia Alves, Lisiana Wachholz Szeneszi, Ana Barradas, Camila Castro Duran, Marília Antunes, Gonçalo Nogueira-Costa, Rita Sousa, Conceição Pinto, Leonor Ribeiro, Catarina Abreu, Sofia Torres, António Quintela, Gadea Mata, Diego Megías, Julie Ribot, Karine Serre, Sandra Casimiro, Bruno Silva-Santos, Lorena Diéguez, Luís Costa
Publikováno v:
Cells, Vol 13, Iss 16, p 1391 (2024)
The combination of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) with endocrine therapy (ET) is the standard-of-care for estrogen receptor (ER)-positive, HER2-negative (ER+/HER2− advanced/metastatic breast cancer (mBC). However, the impact of CD
Externí odkaz:
https://doaj.org/article/7cc338c53f7a4f67ad1bec773c9b99ce
Autor:
Andrea, Bianchi, Damien, Moncelet, François, Lux, Marie, Plissonneau, Silvia, Rizzitelli, Emeline Julie, Ribot, Nawal, Tassali, Véronique, Bouchaud, Olivier, Tillement, Pierre, Voisin, Yannick, Crémillieux
Publikováno v:
NMR in biomedicine. 28(6)
The development of new non-invasive diagnostic and therapeutic approaches is of paramount importance in order to improve the outcome of patients with glioblastoma (GBM). In this work we investigated a completely non-invasive pre-clinical protocol to
Autor:
Pierre Voisin, Emeline Julie Ribot, Sylvain Miraux, Anne-Karine Bouzier-Sore, Jean-François Lahitte, Véronique Bouchaud, Stéphane Mornet, Eric Thiaudière, Jean-Michel Franconi, Lydia Raison, Christine Labrugère, Marie-Hélène Delville
Publikováno v:
Bioconjugate Chemistry; Jul2007, Vol. 18 Issue 4, p1053-1063, 11p